Intradermal delivery of vaccines: potential benefits and current challenges
Intradermal delivery of vaccines: potential benefits and current challenges
复制标题
DOI：
10.2471/blt.10.079426
复制
发表时间：
2011-03-01
期刊：
影响因子：
--
通讯作者：
Kristensen, D
中科院分区：
文献类型：
--
作者：
Hickling, JK;Jones, KR;Kristensen, D
将疫苗抗原递送到人体皮肤的真皮层和/或表皮（即皮内递送）可能比注射到肌肉或皮下组织更有效，从而减少抗原的体积。这就是所谓的剂量节约，并已在一些（但不是全部）疫苗的临床试验中得到证实。节约剂量可能有利于免疫规划，因为它有可能降低疫苗的购买、分发和储存成本；提高疫苗的可得性和有效性。通过皮内注射获得的数据令人鼓舞，值得进一步研究和开发；然而，需要解决知识方面的重大差距和业务挑战，例如重新配方、优化疫苗呈现和开发有助于皮内疫苗递送的新装置。应对皮内分娩的成本和潜在节约进行建模，以提供对潜在效益的现实预期，并支持投资案例。实施和接受皮内疫苗递送需要进一步的研究和开发，这取决于疫苗接种领域多个利益攸关方之间的合作。
Delivery of vaccine antigens to the dermis and/or epidermis of human skin (i.e. intradermal delivery) might be more efficient than injection into the muscle or subcutaneous tissue, thereby reducing the volumes of antigen. This is known as dose-sparing and has been demonstrated in clinical trials with some, but not all, vaccines. Dose-sparing could be beneficial to immunization programmes by potentially reducing the costs of purchase, distribution and storage of vaccines; increasing vaccine availability and effectiveness. The data obtained with intradermal delivery of some vaccines are encouraging and warrant further study and development; however significant gaps in knowledge and operational challenges such as reformulation, optimizing vaccine presentation and development of novel devices to aid intradermal vaccine delivery need to be addressed. Modelling of the costs and potential savings resulting from intradermal delivery should be done to provide realistic expectations of the potential benefits and to support cases for investment. Implementation and uptake of intradermal vaccine delivery requires further research and development, which depends upon collaboration between multiple stakeholders in the field of vaccination.